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The host factor LSF represses the human immunodeficiency virus type 1 long terminal repeat (LTR) by
mediating recruitment of histone deacetylase. We show that pyrrole-imidazole polyamides targeted to the LTR
can specifically block LSF binding both in vitro and within cells via direct access to chromatin, resulting in
increased LTR expression.
Human immunodeficiency virus type 1 (HIV-1) infection is
characterized by cycles of virus production and reinfection
within activated CD4 T lymphocytes. However, HIV estab-
lishes a persistent, nonproductive state within a small popula-
tion of memory CD4 cells (4, 10, 18). Mechanisms that allow
HIV to establish latency are unknown, but modulation of his-
tone architecture within the host genome may participate in
this process. The integrated long terminal repeat (LTR) re-
quires histone acetylation prior to activation, implying a role
for histone deacetylase (HDAC) in establishing or maintaining
quiescence (9). A nucleosome (Nuc-1) protects a region span-
ning 1 to 155 with respect to the start site of transcription
(9, 15, 16).
Three binding motifs for LSF exist within the repressor
complex sequence (RCS) (Fig. 1A and references 13 and 14),
a region from 10 to 27 with respect to the site of LTR
transcription initiation. LSF recruits YY1 to the RCS. YY1
cannot bind the RCS in the absence of LSF. YY1 then recruits
HDAC1, mediating LTR repression (6, 13, 14).
Polyamides are synthetic small molecules containing
N-methylpyrrole and N-methylimidazole amino acids, de-
signed to bind to specific DNA sequences with affinities com-
parable to those of natural DNA-binding transcriptional reg-
ulatory proteins (1–3). Pyrrole-imidazole polyamides can
modulate gene expression by preventing the binding of tran-
scriptional activators or repressors in vitro (7, 8, 12). By using
polyamides, we now directly demonstrate that blockade of LSF
binding in the context of host chromatin increases LTR ex-
pression.
Polyamides (Fig. 1A to C) were synthesized as described
previously (1). Quantitative DNase I footprinting titration as-
says (data not shown) demonstrated that polyamides 1, 2, 3,
and 4 exclusively bound the target sites with equilibrium asso-
ciation constant (Ka) values of 10
9 M1, while mismatch
polyamides M1, M2, and M3/4 containing a single altered
residue bound with Ka values of 10
8 M1. Electrophoresis
mobility shift assays (EMSA) performed as previously de-
scribed (6, 14) demonstrated that 35 to 50 nM of match poly-
amides each specifically inhibited the binding of 60 ng of his-
LSF to the RCS oligonucleotide, while mismatched control
polyamides did not (Fig. 1D and E). As polyamides bind poorly
near the ends of oligonucleotides, RCS-S was used to study
polyamides 3 and 4 and RCS-L was used to study the combi-
nation of polyamide 3 or 4 with polyamide 1 or 2. The potency
of inhibition was increased when polyamides were used in
combination (Fig. 1F). A total of 0.5 M match polyamides
were required to inhibit complex formation at the RCS when
EMSAs were performed with nuclear extract (data not shown).
Multiprotein complexes may be more resistant to inhibition by
polyamides.
We then directly measured the ability of polyamides to spe-
cifically alter promoter occupancy by using chromatin immu-
noprecipitation (ChIP) assays (11, 17). These were performed
as described previously (11) by using a HeLa cell line contain-
ing a single chromosomally integrated copy of the LTR linked
to a chloramphenicol acetyltransferase (CAT) reporter gene
(5). Consistent with results of previous DNase protection stud-
ies (9, 16), ChIP repeatedly demonstrated that histone acety-
lation near Nuc-1 and the RCS increased following treatment
with the HDAC inhibitor trichostatin (TSA) (Fig. 2A). Serial
dilutions of input DNA demonstrated that doubling of the
DNA input results in a less than twofold increase in ChIP PCR
product (11). Therefore, any change of more than twofold was
deemed significant. A greater than fourfold increase in acety-
lated histone H4 near the LTR Nuc-1 site, as measured by
titration of DNA input, was induced by TSA treatment. The
-actin promoter, an additional input control, was little af-
fected by the global effects of TSA and showed changes of
twofold or less (Fig. 2A and data not shown).
To document that polyamides act directly to antagonize LSF
binding to the LTR RCS site in the natural context of host
chromatin, we then performed ChIP assays by using an anti-
LSF antibody (14). Cells were either treated with 400 nM TSA
or were exposed to 2 M polyamides, and then ChIP assays
were performed. The -actin PCR product was equivalent
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before ChIP but, presumably due to the lack of LSF sites at the
-actin promoter, no product was detected after ChIP with
-LSF (data not shown).
As expected, TSA treatment resulted in no change in ChIP
with anti-LSF (Fig. 2B). However, binding polyamides alone
(data not shown) and in combination (Fig. 2B) reproducibly
displaced LSF, as evidenced by a decrease of up to sixfold in
ChIP. A modest, nonspecific increase in ChIP was sometimes
observed when cells are treated with mismatch control poly-
amides. This two- to threefold increase was also observed by
using polyamides targeted to the Ets-1 site of the LTR (8), a
factor that binds in an upstream region of the LTR (data not
shown). This nonspecific effect is most likely due to low-affinity
interactions between polyamides and DNA fragments during
FIG. 1. RCS-binding polyamides specifically inhibit LSF binding to the RCS of the HIV-1 LTR in vitro. (A) Sequences of the RCS (gray)- and
LSF-binding motifs (underlined), sequences targeted by polyamides 1, 2, 3 and 4 (boxed), and oligonucleotide probes (thick lines below) used in
the EMSA. (B) Chemical structure of each polyamide (1, 2, 3, and 4) and their mismatched controls (M1, M2, and M3/4). (C) Ball-and-stick model
of polyamides juxtaposed to their target sites; the Ka value for each molecule is indicated. Polyamide 4 binds in a 3 to 5, N to C orientation as
a single mismatch at a discrete site with high affinity and selectivity. (D) EMSA of RCS alone (lane 1) and that retarded by his-LSF (lane 2). Lanes
3 and 4 show competition by unlabeled RCS or Sp1 consensus binding sequence oligonucleotides (50:1 ratio of competitor to probe), and lanes
5 and 6 show supershift induced by the addition of antibody to LSF or nonspecific immunoglobulin G (IgG). Lanes 7 to 14 show competition by
polyamides 1, 2, M1, and M2 (the concentration of the polyamide is shown). (E) EMSA of RCS-S (4 to 35) alone (lane 1) and that retarded
by his-LSF (lane 2), and competition by RCS or Sp1 (lanes 3 and 4), polyamide 3 (lanes 5 and 6), or M3/4 (lanes 7 and 8). (F) EMSA of RCS-L
(10 to 34) alone (lane 1) and that retarded by his-LSF (lane 2), and competition by RCS or Sp1 (lanes 3 and 4), polyamides 1 and 3 (lanes
5 and 6), M1 and M3/4 (lanes 7 and 8), 2 and 3 (lanes 9 and 10), or M2 and M3/4 (lanes 11 and 12).
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ChIP. Nevertheless, the potent ability of specific RCS-binding
polyamides to inhibit LSF binding results in an overall de-
crease in ChIP. Transfection of cells with a dominant-negative
LSF construct, capable of forming inactive LSF heterodimers
and blocking repression at the RCS (6), induced markedly
diminished LSF occupancy at the RCS in ChIP assays (11).
Therefore, ChIP of LSF at the RCS is inhibited both by spe-
cific polyamide blockade of the LSF binding site and by inhib-
iting the ability of LSF to bind this DNA site. These findings
provide further evidence not only of the sequence-specific na-
ture of polyamides and the specificity of the ChIP assay but
they are also the first direct evidence that polyamides access
chromatin and affect transcription factor occupancy within a
living cell.
To illustrate that RCS-binding polyamides could affect basal
LTR expression we studied the T-cell line HUT78-LTR-GFP
(provided by J. V. Garcia), which contains an integrated HIV-1
LTR promoter linked to a green fluorescence protein (GFP)
reporter gene. Cells were synchronized in media with 0.5%
serum overnight, refed, and exposed to RCS-binding poly-
amides or mismatch control polyamides for 4 h. Mean GFP
fluorescence intensity was then calculated. Fluorescence was
not increased significantly (5%) by mismatch control poly-
amides but was increased by up to 14-fold by RCS-binding
polyamides (Fig. 3A).
To verify that polyamides induced a corresponding increase
in viral production we tested the chronically infected ACH2
cell line (Fig. 3B). Cells were again synchronized in 0.5%
serum overnight, refed, and exposed to RCS-binding poly-
amides, mismatch control polyamides, or TSA for 24 h. RCS-
binding polyamides, but not mismatch polyamides, resulted in
an increase in p24 production comparable to the effect of TSA.
Finally, as overexpression of YY1 can inhibit Tat-mediated
LTR activation (6, 13, 14) we tested whether RCS-binding
polyamides could block repression mediated by YY1. HeLa
cells containing a single integrated LTR-CAT reporter gene
were transfected as previously described (6) and were incu-
bated with 2 M polyamides. RCS-binding polyamides specif-
FIG. 1—Continued.
VOL. 76, 2002 NOTES 12351
ically blunted the ability of YY1 to block Tat activation (Fig.
3C).
In summary, we show that RCS-binding polyamides targeted
to the HIV LTR can inhibit LSF binding to the RCS in vitro
and can increase expression of the LTR. RCS-binding poly-
amides selectively upregulate expression of the integrated
HIV-1 promoter in three different model systems. We ob-
served increasing expression in HUT78 T cells in the absence
of Tat and in viral expression in the ACH2 model of persistent
infection, and we observed relief of YY1-induced repression in
the HeLa LTR-CAT reporter system. Pyrrole-imidazole poly-
amides, which are synthetic cell-permeable small molecules,
are novel and useful tools to inhibit the DNA-binding activity
of transcription factors and directly modulate target gene ac-
tivity in a living cell.
Our findings suggest that YY1, LSF, and HDAC1 may play
an ongoing, active role in the establishment or maintenance of
viral latency. Occupancy of the repressor complex at the LTR
may exist in a state of equilibrium, with increased occupancy
resulting in HDAC1 recruitment, nucleosome deacetylation,
and transcriptional repression. Studies of primary cells ob-
tained from HIV-infected donors to validate this model are
ongoing.
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rabbit immunoglobulin G (IgG) and control PCR amplification of the
5 LTR or -actin promoter using extract prior to immunoprecipita-
tion. Results are representative of three independent experiments.
(B) ChIP with anti-LSF. PCR products of extracts of untreated cells,
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or M2 and M3/4. Shown are products of ChIP and PCR amplification
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(B) HIV-1 p24 gag production was measured in triplicate cultures of
ACH2 cells after 24 h of exposure to polyamide 2 or M2, 100 nM TSA,
or medium control. An asterisk indicates statistically significant differ-
ence from the results of the control culture (P  0.05 by unpaired t
test). (C) Expression of the integrated reporter gene in HeLa-LTR-
CAT can be activated by transfection of Tat, and this activation is
blunted by cotransfection of YY1 (6, 11, 14). Inhibition of pAR-Tat
activation (50 ng) by CMV-YY1 (1.5 g) is expressed as 100%. The
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amide M1 is displayed. An asterisk indicates statistically significant
difference from 100% repression (P  0.05). Results of four indepen-
dent transfections are shown.
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